Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Ipilimumab in High-Risk Stage III Melanoma
NCT00636168Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2008
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Jun 2008; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00636168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636168.